Evidence map›Paper›PMID 35431581›Full record

ReviewCancer management and research2022

Technological Advancements in External Beam Radiation Therapy (EBRT): An Indispensable Tool for Cancer Treatment.

Krishna Koka, Amit Verma, Bilikere S Dwarakanath, Rao V L Papineni

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer management and research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Taste disorders in cancer patients and current therapeutic approaches: a narrative review of an understudied topic in supportive care.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Krishna KokaPenn State University, Pennsylvania, PA, USA.
Amit VermaPACT & Health LLC, Branford, CT, USA.
Bilikere S DwarakanathCentral Research Facility, Sri Ramachandra Institute of Higher Education and Research Porur, Chennai, India.
Rao V L PapineniPACT & Health LLC, Branford, CT, USA.

Funding

TOPIC 366: I-PARTS INTEGRATED PLATFORM FOR ANTI-CANCER RADIATION THERAPEUTICS SCREENING75N91019C00043 · NCI · PACT AND HEALTH, LLC · PI PAPINENI, LAKSHMAN RAO · 2019 to 2019
$2.0M
Topic 394 - A versatile radiation-triggered phosphor platform for localized anti-cancer therapy75N91019C00016 · NCI · PACT AND HEALTH, LLC · PI PAPINENI, RAO · 2019 to 2019
$300k
NCI NIH HHS 75N91019C00016NCI NIH HHS 75N91019C00043
6 · The paper itself

Abstract

Recent technological advancements have increased the efficacy of radiotherapy, leading to effective management of cancer patients with enhanced patient survival and improved quality of life. Several important developments like multileaf collimator, integration of imaging techniques like positron emission tomography (PET) and computed tomography (CT), involvement of advanced dose calculation algorithms, and delivery techniques have increased tumor dose distribution and decreased normal tissue toxicity. Three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), stereotactic radiotherapy, image-guided radiotherapy (IGT), and particle therapy have facilitated the planning procedures, accurate tumor delineation, and dose estimation for effective personalized treatment. In this review, we present the technological advancements in various types of EBRT methods and discuss their clinical utility and associated limitations. We also reveal novel approaches of using biocompatible yttrium oxide scintillator-photosensitizer complex (YSM) that can generate X-ray induced cytotoxic reactive oxygen species, facilitating X-ray activated photodynamic therapy (XPDT (external beam) and/or iXPDT (internal X-ray source)) and azido-derivatives of 2-deoxy-D-glucose (2-DG) as agents for site-specific radiation-induced DNA damage.

Indexed as

2-AZ-2-DG2-azido-2-deoxy-D-glucose2-deoxy-D-glucose2-DGcomputed tomographyexternal beamradiotherapy

Identifiers

PMID35431581
PMCPMC9012312

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.